Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Medical Officer | February 02, 2026 | February 04, 2026 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | SVP and Chief Medical Officer | March 15, 2019 | March 18, 2019 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 948,432 |
Ending reported balance
After 2026-02-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-02 · Sale · Disposed 21,582 · Balance 994,508 F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. Row 2 · 2026-02-02 · Sale · Disposed 25,375 · Balance 969,133 F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Row 3 · 2026-02-02 · Sale · Disposed 20,701 · Balance 948,432 F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F4: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
F4: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.
Protara Therapeutics, Inc.
Report date March 15, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,584 |
Reported balance
After 2019-03-15 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2019-03-15 · Gift · Disposed 7,334 · Balance 116,584 F1: This transaction involved a gift of securities by the reporting person to the William Conroy Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 109,251 |
Reported balance
After 2019-03-15 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2019-03-15 · Gift · Disposed 7,333 · Balance 109,251 F2: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 101,917 |
Reported balance
After 2019-03-15 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2019-03-15 · Gift · Disposed 7,333 · Balance 101,917 F3: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 18,999 |
Reported balance
After 2019-03-15 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-03-15 · Gift · Acquired 7,333 · Balance 18,999 F2: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,332 |
Reported balance
After 2019-03-15 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-03-15 · Gift · Acquired 7,333 · Balance 26,332 F3: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of securities by the reporting person to the William Conroy Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F2: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F3: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
SCYNEXIS INC
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,750 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 5,750 · Balance 5,750 F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each RSU upon vesting. 1/3rd of the RSUs will vest annually on the anniversary of the date of grant, with the first 1/3rd vesting on September 18, 2027, provided that the Reporting Person is providing continuous services on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2036-09-18 | Direct | 5,750 |
Reported balance
After 2026-09-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-18 · Grant · Acquired 5,750 · Balance 5,750 F2: One third of the shares subject to this option vest on the one year anniversary of the grant date, and 1/36 of the shares subject to the option vest on each of the next 24 months thereafter provided that the Reporting Person is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each RSU upon vesting. 1/3rd of the RSUs will vest annually on the anniversary of the date of grant, with the first 1/3rd vesting on September 18, 2027, provided that the Reporting Person is providing continuous services on the applicable vesting date.
F2: One third of the shares subject to this option vest on the one year anniversary of the grant date, and 1/36 of the shares subject to the option vest on each of the next 24 months thereafter provided that the Reporting Person is providing continuous services on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001193125-26-397873 · ownership.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2036-09-18 F2 · derivative.exercise_date: One third of the shares subject to this option vest on the one year anniversary of the grant date, and 1/36 of the shares subject to the option vest on each of the next 24 months thereafter provided that the Reporting Person is providing continuous services on the applicable vesting date. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 20:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-397873 · ownership.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each RSU upon vesting. 1/3rd of the RSUs will vest annually on the anniversary of the date of grant, with the first 1/3rd vesting on September 18, 2027, provided that the Reporting Person is providing continuous services on the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 20,701 | $1.39 | $28,774.39 |
DisclosureSEC source: 0001619834-26-000002 · primarydocument.xml · nonDerivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 948,432 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 25,375 | $1.39 | $35,271.25 |
DisclosureSEC source: 0001619834-26-000002 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 969,133 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:13 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 21,582 | $1.39 | $29,998.98 |
DisclosureSEC source: 0001619834-26-000002 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994,508 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:41 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 320,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001619834-26-000001 · primarydocument.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2036-01-30 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:41 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 204,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001619834-26-000001 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016,090 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,144 | $1.83 | $13,073.52 |
DisclosureSEC source: 0001562180-25-001997 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 809,090 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:53 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 27,236 | $2.10 | $57,195.60 |
DisclosureSEC source: 0001562180-25-000916 · primarydocument.xml · nonDerivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 816,234 F4 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:53 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 23,270 | $2.10 | $48,867.00 |
DisclosureSEC source: 0001562180-25-000916 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 843,470 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. F4 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:53 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 292,300 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001562180-25-000916 · primarydocument.xml · derivative · entry 4 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,300 Underlying: Common Stock · 292,300 shares Expires 2035-01-31 F6 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:53 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 194,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000916 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 866,740 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2024 and 1,500 shares of the Issuer's common stock purchased on December 31, 2024, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:46 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,169 | $1.58 | $11,327.02 |
DisclosureSEC source: 0001562180-24-002020 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,840 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 8,367 | $1.52 | $12,717.84 |
DisclosureSEC source: 0001562180-24-001993 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 703,009 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 24,311 | $1.68 | $40,842.48 |
DisclosureSEC source: 0001562180-24-000970 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 711,376 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 303,300 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000970 · primarydocument.xml · derivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,300 Underlying: Common Stock · 303,300 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 202,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000970 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,687 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| August 25, 2023 Filed May 9, 2024 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 27,000 | $1.15 | $31,050.00 |
DisclosureSEC source: 0001562180-24-003948 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,840 Read SEC document |
| May 16, 2023 Filed May 18, 2023 22:20 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 63,567 | $1.07 | $67,889.56 |
DisclosureSEC source: 0001562180-23-004254 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,487 F1 · shares: This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted "sell-to-cover" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on May 12, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,110 | $0.88 | $974.03 |
DisclosureSEC source: 0001562180-23-002199 · primarydocument.xml · nonDerivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,054 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,400 | $0.88 | $5,616.00 |
DisclosureSEC source: 0001562180-23-002199 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,164 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,613 | $0.88 | $5,802.91 |
DisclosureSEC source: 0001562180-23-002199 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,564 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,539 | $0.81 | $6,130.71 |
DisclosureSEC source: 0001562180-23-002040 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,177 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 294,300 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001562180-23-000830 · primarydocument.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,300 Underlying: Common Stock · 294,300 shares Expires 2033-01-31 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 196,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000830 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,716 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on December 30, 2022 under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 20:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,147 | $0.36 | $415.79 |
DisclosureSEC source: 0001562180-22-006402 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,016 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on August 30, 2019. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022, under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| May 12, 2022 Filed May 16, 2022 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001562180-22-004031 · primarydocument.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-05-12 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. Read SEC document |
| May 12, 2022 Filed May 16, 2022 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004031 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,663 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,100 | $2.17 | $2,387.77 |
DisclosureSEC source: 0001562180-22-002165 · primarydocument.xml · nonDerivative · entry 4 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,663 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. F5 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on December 31, 2021, under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,556 | $2.17 | $14,231.11 |
DisclosureSEC source: 0001562180-22-002165 · primarydocument.xml · nonDerivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,263 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 225,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002165 · primarydocument.xml · derivative · entry 5 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-02-28 F6 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002165 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,819 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,400 | $2.15 | $15,945.52 |
DisclosureSEC source: 0001562180-22-002165 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,819 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,042 | $2.83 | $2,948.86 |
DisclosureSEC source: 0001562180-21-005744 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,219 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on August 30, 2019. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2021 under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 00:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,081 | $3.40 | $3,675.40 |
DisclosureSEC source: 0001562180-21-002539 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,761 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002353 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,842 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,558 | $3.40 | $25,667.72 |
DisclosureSEC source: 0001562180-21-001781 · primarydocument.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,442 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001781 · primarydocument.xml · derivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-26 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001781 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 105,500 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001930 · primarydocument.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,500 Underlying: Common Stock · 105,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001930 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 11:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | PurchaseCommon Stock | 27,000 | $3.58 | $96,660.00 |
DisclosureSEC source: 0001562180-19-005640 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · kind: The purchase reported in this Form 4 was made on the open market. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.50 to $3.64, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 20:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 250,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001562180-19-004618 · primarydocument.xml · derivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-08-30 F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 20:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004618 · primarydocument.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 12:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GiftCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001780 · ownership.xml · nonDerivative · entry 5 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 26,332 F3 · kind: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F3 · shares: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 12:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GiftCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001780 · ownership.xml · nonDerivative · entry 4 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,999 F2 · kind: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F2 · shares: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 12:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GiftCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001780 · ownership.xml · nonDerivative · entry 3 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,917 F3 · kind: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F3 · shares: This transaction involved a gift of securities by the reporting person to the Steven Edward Burke Irrevocable Trust u/a 11/15/2000, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 12:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GiftCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001780 · ownership.xml · nonDerivative · entry 2 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,251 F2 · kind: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F2 · shares: This transaction involved a gift of securities by the reporting person to the Timothy Andrew Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son, who is deemed to share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 12:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GiftCommon Stock | 7,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001780 · ownership.xml · nonDerivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,584 F1 · kind: This transaction involved a gift of securities by the reporting person to the William Conroy Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. F1 · shares: This transaction involved a gift of securities by the reporting person to the William Conroy Burke Irrevocable Trust u/a 12/28/1998, an irrevocable trust established by the reporting person for the benefit of his son. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:17 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001171843-19-000435 · ownership.xml · derivative · entry 1 Burke Steven Keith · CIK 0001619834 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, $0.001 par value · 145,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.